Oral IC/BPS Agents
Category: Pharmacology → Bladder Pain & IC/BPS
Overview
The 2022 AUA guideline lists amitriptyline, cimetidine, hydroxyzine and pentosan polysulfate (PPS) as oral options, without ranking them. Its previous numbered treatment tiers were removed; selection and combinations depend on symptoms, comorbidities and patient preferences.[1][2]
PPS requires particular reconsideration: the 2025 CUA guideline conditionally recommends against oral PPS, judging its small benefit unfavorable against potentially serious visual harm and cost. This differs from its retained option status in AUA 2022. CUA made no recommendation for or against cyclosporine because of insufficient evidence.[12]
This page covers the oral agents as a pharmacology class. For the broader condition — diagnosis, phenotyping, and the full multimodal algorithm — see IC/BPS.
Mechanism of Action
Five distinct mechanistic classes target different points in the IC/BPS cascade:
| Agent | Class | Principal mechanism |
|---|---|---|
| Amitriptyline | Tricyclic antidepressant | Central analgesia (NE/5-HT reuptake inhibition), antihistamine (H1), anticholinergic (M1), sodium-channel modulation |
| Pentosan polysulfate (PPS) | Semisynthetic GAG analog | Proposed urothelial barrier protection; the clinical mechanism is not established |
| Hydroxyzine | H1 antihistamine | Mast-cell stabilization; histamine-H1 receptor blockade |
| Cimetidine | H2 antagonist | Mast-cell / H2 receptor effects; immune modulation (less well characterized) |
| Cyclosporine A | Calcineurin inhibitor | Calcineurin inhibition reduces T-cell activation; not a selective B-cell treatment |
Agents in This Class
| Generic Name | Brand / Key Names | Route | Status | Notes |
|---|---|---|---|---|
| Amitriptyline | Elavil (historical) | PO | Off-label | Option when pain and sleep disturbance are treatment targets |
| Pentosan polysulfate sodium | Elmiron | PO | FDA-approved for IC (1996) | Only FDA-approved oral agent; maculopathy risk |
| Hydroxyzine | Atarax, Vistaril | PO | Off-label | Sometimes selected for allergic/atopic symptoms; efficacy uncertain |
| Cimetidine | Tagamet | PO | Off-label | Many CYP450 drug interactions |
| Cyclosporine A | Neoral, Sandimmune, Gengraf | PO | Off-label | Selected refractory cases; nephrotoxicity and monitoring burden |
Indications in Reconstructive Urology
Primary: symptom treatment for patients meeting IC/BPS criteria, alongside education, self-care and other appropriate therapies.[1]
Phenotype-directed use:
- Hunner-lesion IC/BPS — AUA permits oral cyclosporine, particularly when lesions are refractory to fulguration and/or triamcinolone. Its toxicity requires careful selection; superiority for the Hunner phenotype has not been established.[1][4][12]
- Pain-dominant, sleep-disturbed, or comorbid neuropathic-pain presentations — amitriptyline may be selected for its analgesic and sedating effects.[5]
- Allergic/atopic phenotype (elevated urinary histamine, coexisting dermatologic allergy) — hydroxyzine is the conceptual fit, though controlled evidence is weak.[6]
- Non-Hunner disease — choose a time-limited trial according to symptoms and harms; no oral drug reliably predicts response. Discuss the updated PPS benefit–risk balance before prescribing.[1][12]
Dosing & Administration
Doses listed are for reference only. Confirm with current guidelines and institutional protocols. TCA, antihistamine, and immunosuppressant dosing must be individualized to patient comorbidities, concomitant medications, and renal/hepatic function.
| Agent | Starting dose | Titration target | Duration before judging efficacy |
|---|---|---|---|
| Amitriptyline | 10–25 mg PO qhs | 50–75 mg qhs as tolerated | 6–12 weeks |
| Pentosan polysulfate | 100 mg PO TID with water, at least 1 hour before or 2 hours after meals | No routine titration | Reassess at 3 months; the label allows another 3 months if unimproved but tolerating. Benefit–risk beyond 6 months in nonresponders is unknown.[13] |
| Hydroxyzine | 10–25 mg PO qhs | Common IC/BPS regimens use up to 50 mg qhs; assess sedation, age and QT risk | Reassess response and tolerability within weeks.[15] |
| Cimetidine | 400 mg PO BID | — | 4–8 weeks |
| Cyclosporine A | Published IC/BPS regimens commonly use 2–3 mg/kg/day divided BID | Specialist-adjusted dosing according to renal function, BP, interactions and protocol-specific drug levels | Assess benefit and toxicity regularly; not a routine empiric prescription.[4][15] |
General principles:
- Start low and titrate — particularly for TCA and hydroxyzine where sedation is dose-limiting
- PPS requires baseline retinal exam and periodic follow-up (see maculopathy below)
- Cyclosporine requires baseline and serial BP, renal function (Cr, eGFR), CBC, LFTs, electrolytes (Mg, K), and trough level monitoring
- Do not force amitriptyline escalation when anticholinergic effects or sedation outweigh benefit
- Failure of one agent does not predict failure of another — sequential or combination trials are reasonable[1][2]
Contraindications & Precautions
Amitriptyline
- Contraindicated: recent MI, uncorrected QT prolongation, concurrent MAOI use (2-week washout)
- Caution: narrow-angle glaucoma, BPH with retention risk, cardiac conduction disease, serotonergic polypharmacy (serotonin syndrome), elderly (anticholinergic burden, falls)
- Typical side effects: dry mouth, constipation, sedation, weight gain, orthostasis, urinary retention (ironic in this population)
Pentosan polysulfate
- Label warning (not a boxed warning): potentially irreversible pigmentary maculopathy. Cumulative exposure is a risk factor, and retinal changes may progress after stopping treatment.[7][8][9]
- US label screening: obtain an ophthalmologic history. With preexisting eye disease, obtain a comprehensive retinal examination before starting. For all patients, the label suggests baseline OCT and fundus autofluorescence within 6 months and periodic follow-up; it does not set a universal annual interval. Reassess continued treatment if pigmentary changes develop and continue retinal follow-up after cessation because progression can occur.[13]
- Bleeding risk: PPS has weak anticoagulant activity — caution with concurrent anticoagulants, NSAIDs, or bleeding disorders.
- Hepatic dysfunction reported; consider liver disease and abnormal tests in the prescribing assessment.
A Korean claims-based cohort included 103,553 PPS users and 205,792 nonusers with cystitis. PPS exposure was associated with subsequent maculopathy (adjusted HR 1.34, 95% CI 1.31–1.38). This observational association reinforces the safety concern; it is not a 34% absolute risk or a patient-specific prediction.[14]
Hydroxyzine
- Contraindicated: early pregnancy, known QT prolongation (dose-dependent QTc effect)
- Caution: elderly (sedation, anticholinergic burden), concurrent CNS depressants
Cimetidine
- Significant CYP450 inhibition — major drug-interaction profile (warfarin, phenytoin, theophylline, TCAs, benzodiazepines, β-blockers, opioids). Review the full medication list before prescribing.
- Caution: elderly (confusion), renal impairment (dose reduction), concurrent antiarrhythmics
Cyclosporine A
- Contraindicated: uncontrolled hypertension, renal impairment, active infection, malignancy (relative)
- Monitoring-dependent: baseline and repeated BP, renal function, electrolytes and other laboratory assessment under the prescribing specialist. Drug-level targets and monitoring intervals depend on the regimen; there is no universal IC/BPS trough target.[1][15]
- Major drug interactions via CYP3A4 (statins — rhabdomyolysis; macrolides; azoles; grapefruit juice)
- Long-term risks: nephrotoxicity, hypertension, gingival hyperplasia, hypertrichosis, increased infection and malignancy risk
Perioperative Considerations
| Agent | Periop action | Rationale |
|---|---|---|
| Amitriptyline | Generally continue; document for anesthesia | Anticholinergic burden, QT, orthostasis — coordinate with anesthesia if prolonged operation or cardiac comorbidity |
| PPS | Agree stop/restart timing with the procedural team | Weak anticoagulant activity; the label advises discussing surgery, not a universal 7-day hold.[13] |
| Hydroxyzine | Continue; often held day-of for PONV drugs | Additive sedation with anesthetics |
| Cimetidine | Continue; flag CYP450 interactions to pharmacy | Can alter anesthetic drug levels |
| Cyclosporine A | Discuss with transplant/rheum prescribing colleague | Perioperative infection risk; wound healing; nephrotoxicity under hemodynamic stress — do not hold without discussion given flare risk |
Evidence Summary
| Agent | Evidence | Key reference |
|---|---|---|
| PPS | FDA-approved, but RCT efficacy is inconsistent and retinal toxicity changes its benefit–risk balance. CUA 2025 conditionally recommends against use.[12] | Sant 2003 ICCTG[6]; Hall 2025[7] |
| Amitriptyline | Foster 2010 (n=271): primary intention-to-treat response 55% vs 45% with placebo (p=0.12). A subgroup reaching at least 50 mg showed 66% vs 47% response, but that subgroup comparison was not prespecified. | Foster 2010[5]; Di 2021[3] |
| Hydroxyzine | Sant 2003 ICCTG RCT — hydroxyzine alone or with PPS did not show significant benefit over placebo. Commonly used on expert-opinion basis. | Sant 2003[6] |
| Cimetidine | Small RCT (Thilagarajah 2001, n=34) — pain and symptom improvement vs placebo. Limited subsequent validation. | Thilagarajah 2001[10] |
| Cyclosporine A | A small comparative trial favored cyclosporine over PPS. Network rankings suggest benefit but do not establish the best drug or a phenotype-specific advantage; toxicity limits use.[12] | Sairanen 2005[4]; Di 2021[3] |
| Cochrane overview | 81 RCTs (4,674 participants), mostly small studies. Low or very low certainty for most treatment comparisons; benefit for PPS and several other treatments remains uncertain. | Imamura 2020[11] |
Practical Pearls
- Amitriptyline dosing — 10 mg qhs for 1 week then 25 mg for 2–4 weeks before judging. Titrate to 50–75 mg only if tolerating. The exploratory higher-dose subgroup does not overturn the trial's nonsignificant primary outcome or prove that non-tolerance alone caused it.[5]
- PPS counseling is non-negotiable — the maculopathy conversation (and documentation of it) must happen before the first prescription. Arrange retinal assessment according to the label and the patient's ocular history. Some patients will decline PPS on this basis — that is a reasonable choice.[7][8]
- Cimetidine before famotidine — for this indication specifically; the IC/BPS literature is with cimetidine, not substituted H2 blockers. The trade-off is cimetidine's drug-interaction profile.
- Cyclosporine needs a team — don't start it without a rheumatologist, transplant nephrologist, or IC-experienced colleague to help with monitoring and dose adjustment. Failure to monitor is how patients lose kidney function.[4]
- Reassess benefit and harms — agree an agent-specific review point and stop ineffective treatment. If PPS is chosen after counseling, follow its 3- and 6-month reassessment instructions rather than continuing an ineffective course indefinitely.[1][13]
- Sequential trials are normal — patients may cycle through 2–3 agents before finding one that helps. Document why each was chosen and why each was discontinued.
- Combination therapy is common in practice even without strong trial support — e.g., amitriptyline + PPS, or amitriptyline + hydroxyzine for overlapping sleep/allergy symptoms.[1][2]
See Also
- IC/BPS — full condition article
- Intravesical IC/BPS Agents — DMSO, lidocaine, heparin, HA, chondroitin
- Assessment Tools & Questionnaires — ICSI, ICPI, GUPI, VAS for response measurement
References
1. Clemens JQ, Erickson DR, Varela NP, Lai HH. "Diagnosis and Treatment of Interstitial Cystitis/Bladder Pain Syndrome." J Urol. 2022;208(1):34-42. doi:10.1097/JU.0000000000002756
2. Chermansky CJ, Guirguis MO. "Pharmacologic Management of Interstitial Cystitis/Bladder Pain Syndrome." Urol Clin North Am. 2022;49(2):273-282. doi:10.1016/j.ucl.2022.01.003
3. Di XP, Luo DY, Jin X, et al. "Efficacy and Safety Comparison of Pharmacotherapies for Interstitial Cystitis and Bladder Pain Syndrome: A Systematic Review and Bayesian Network Meta-Analysis." Int Urogynecol J. 2021;32(5):1129-1141. doi:10.1007/s00192-020-04659-w
4. Sairanen J, Tammela TL, Leppilahti M, et al. "Cyclosporine A and Pentosan Polysulfate Sodium for the Treatment of Interstitial Cystitis: A Randomized Comparative Study." J Urol. 2005;174(6):2235-8. doi:10.1097/01.ju.0000181808.45786.84
5. Foster HE Jr, Hanno PM, Nickel JC, et al. "Effect of Amitriptyline on Symptoms in Treatment Naïve Patients With Interstitial Cystitis/Painful Bladder Syndrome." J Urol. 2010;183(5):1853-8. doi:10.1016/j.juro.2009.12.106
6. Sant GR, Propert KJ, Hanno PM, et al. "A Pilot Clinical Trial of Oral Pentosan Polysulfate and Oral Hydroxyzine in Patients With Interstitial Cystitis." J Urol. 2003;170(3):810-815. doi:10.1097/01.ju.0000083020.06212.3d
7. Hall BP, Shiromani S, Vanderbeek BL, et al. "Pentosan Polysulfate Maculopathy: Clinical Considerations, Pathobiology, and Causality." Prog Retin Eye Res. 2025:101400. doi:10.1016/j.preteyeres.2025.101400
8. McGwin G, MacLennan P, Owsley C. "Association Between Pentosan Polysulfate Sodium and Retinal Disorders." JAMA Ophthalmol. 2022;140(1):37-42. doi:10.1001/jamaophthalmol.2021.4778
9. Lindeke-Myers A, Hanif AM, Jain N. "Pentosan Polysulfate Maculopathy." Surv Ophthalmol. 2022;67(1):83-96. doi:10.1016/j.survophthal.2021.05.005
10. Thilagarajah R, Witherow RO, Walker MM. "Oral Cimetidine Gives Effective Symptom Relief in Painful Bladder Disease: A Prospective, Randomized, Double-Blind Placebo-Controlled Trial." BJU Int. 2001;87(3):207-12. doi:10.1046/j.1464-410x.2001.02031.x
11. Imamura M, Scott NW, Wallace SA, et al. "Interventions for Treating People With Symptoms of Bladder Pain Syndrome: A Network Meta-Analysis." Cochrane Database Syst Rev. 2020;7:CD013325. doi:10.1002/14651858.CD013325.pub2
12. Doiron RC, Tadayon B, Violette PD, et al. "2025 Canadian Urological Association Guideline: Selected treatment recommendations for interstitial cystitis/bladder pain syndrome." Can Urol Assoc J. 2025;19(4):90–103. doi:10.5489/cuaj.9182
13. Janssen Pharmaceuticals. ELMIRON (pentosan polysulfate sodium) US prescribing information. Revised July 2024; accessed September 11, 2026.
14. Kim MS, Choi YJ, Ji E, et al. "Association between Pentosan Polysulfate and Subsequent Maculopathy: Insights from a Nationwide Population-Based Study in Korea." Ophthalmology. 2025;132(1):108–114. doi:10.1016/j.ophtha.2024.07.027
15. Cox A, Golda N, Nadeau G, et al. "CUA guideline: Diagnosis and treatment of interstitial cystitis/bladder pain syndrome." Can Urol Assoc J. 2016;10(5–6):E136–E155. Full text. Historical dose examples; updated treatment positioning is in the 2025 guideline above.